The IMPROVE trial demonstrates that starting a one-month isoniazid-rifapentine (1HP) course during hospitalization for cryptococcal meningitis is as safe and effective as outpatient initiation, potentially increasing treatment completion rates in high-risk patients with advanced HIV.